image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - CA
$ 7.44
-2.75 %
$ 2.74 B
Market Cap
-15.5
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one BHC stock under the worst case scenario is HIDDEN Compared to the current market price of 7.44 USD, Bausch Health Companies Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one BHC stock under the base case scenario is HIDDEN Compared to the current market price of 7.44 USD, Bausch Health Companies Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one BHC stock under the best case scenario is HIDDEN Compared to the current market price of 7.44 USD, Bausch Health Companies Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
8.76 B REVENUE
7.79%
963 M OPERATING INCOME
-29.71%
-611 M NET INCOME
-188.21%
1.03 B OPERATING CASH FLOW
241.76%
-2.14 B INVESTING CASH FLOW
-607.92%
1.48 B FINANCING CASH FLOW
411.18%
2.51 B REVENUE
4.47%
318 M OPERATING INCOME
-25.34%
-92 M NET INCOME
-920.19%
411 M OPERATING CASH FLOW
8.56%
-102 M INVESTING CASH FLOW
-29.18%
-189 M FINANCING CASH FLOW
55.36%
Balance Sheet Bausch Health Companies Inc.
image
Current Assets 5.6 B
Cash & Short-Term Investments 947 M
Receivables 2 B
Other Current Assets 2.65 B
Non-Current Assets 21.8 B
Long-Term Investments 10.7 M
PP&E 1.71 B
Other Non-Current Assets 20 B
Current Liabilities 4.3 B
Accounts Payable 719 M
Short-Term Debt 450 M
Other Current Liabilities 3.13 B
Non-Current Liabilities 23.1 B
Long-Term Debt 21.9 B
Other Non-Current Liabilities 1.19 B
EFFICIENCY
Earnings Waterfall Bausch Health Companies Inc.
image
Revenue 8.76 B
Cost Of Revenue 2.56 B
Gross Profit 6.2 B
Operating Expenses 5.24 B
Operating Income 963 M
Other Expenses 1.57 B
Net Income -611 M
RATIOS
70.78% GROSS MARGIN
70.78%
11.00% OPERATING MARGIN
11.00%
-6.76% NET MARGIN
-6.76%
57.93% ROE
57.93%
-2.16% ROA
-2.16%
7.06% ROIC
7.06%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bausch Health Companies Inc.
image
Net Income -611 M
Depreciation & Amortization 1.26 B
Capital Expenditures -272 M
Stock-Based Compensation 132 M
Change in Working Capital -582 M
Others 555 M
Free Cash Flow 760 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bausch Health Companies Inc.
image
Wall Street analysts predict an average 1-year price target for BHC of $10.4 , with forecasts ranging from a low of $7 to a high of $16 .
BHC Lowest Price Target Wall Street Target
7 USD -5.91%
BHC Average Price Target Wall Street Target
10.4 USD 40.17%
BHC Highest Price Target Wall Street Target
16 USD 115.05%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Bausch Health Companies Inc.
image
Sold
0-3 MONTHS
3.67 K USD 1
3-6 MONTHS
83 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
61.9 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Dec 02, 2024
Sell 3.67 K USD
Carson Seana
EVP, General Counsel
- 440
8.35 USD
4 months ago
Sep 06, 2024
Sell 83 K USD
Carson Seana
EVP, General Counsel
- 13370
6.21 USD
10 months ago
Mar 04, 2024
Sell 43.3 K USD
Carson Seana
EVP, General Counsel
- 4420
9.8 USD
10 months ago
Mar 04, 2024
Sell 1.95 K USD
Carson Seana
EVP, General Counsel
- 199
9.8 USD
10 months ago
Mar 04, 2024
Sell 15.3 K USD
Carson Seana
EVP, General Counsel
- 1561
9.8 USD
10 months ago
Mar 04, 2024
Sell 1.3 K USD
Carson Seana
EVP, General Counsel
- 133
9.8 USD
1 year ago
Dec 05, 2023
Sell 1.62 K USD
Carson Seana
EVP, General Counsel
- 220
7.38 USD
1 year ago
Nov 06, 2023
Sell 327 USD
Carson Seana
EVP, General Counsel
- 43
7.61 USD
1 year ago
Sep 06, 2023
Sell 55.4 K USD
Carson Seana
EVP, General Counsel
- 6685
8.28 USD
1 year ago
Mar 03, 2023
Sell 7.29 K USD
Carson Seana
EVP, General Counsel
- 780
9.34 USD
1 year ago
Mar 06, 2023
Sell 4.54 K USD
Carson Seana
EVP, General Counsel
- 495
9.17 USD
1 year ago
Feb 28, 2023
Sell 2.72 K USD
Carson Seana
EVP, General Counsel
- 292
9.32 USD
2 years ago
Apr 14, 2022
Sell 35.4 K USD
Spurr Robert
U.S. President-Pharma Business
- 1595
22.19 USD
2 years ago
Mar 15, 2022
Sell 108 K USD
Spurr Robert
U.S. President-Pharma Business
- 4846
22.2 USD
2 years ago
Mar 08, 2022
Sell 84.6 K USD
Gordon Joseph F
Pres&Co-Head Bausch&Lomb/Int'l
- 3889
21.76 USD
2 years ago
Mar 02, 2022
Sell 259 K USD
Gordon Joseph F
Pres&Co-Head Bausch&Lomb/Int'l
- 11077
23.37 USD
2 years ago
Mar 02, 2022
Sell 37.3 K USD
Spurr Robert
U.S. President-Pharma Business
- 1595
23.37 USD
2 years ago
Mar 01, 2022
Sell 151 K USD
Gordon Joseph F
Pres&Co-Head Bausch&Lomb/Int'l
- 6338
23.82 USD
2 years ago
Feb 15, 2022
Sell 81.3 K USD
Spurr Robert
U.S. President-Pharma Business
- 3251
25.02 USD
3 years ago
Jan 18, 2022
Sell 86.6 K USD
Spurr Robert
U.S. President-Pharma Business
- 3251
26.63 USD
3 years ago
Nov 30, 2021
Bought 1.21 M USD
Miller Steven D
Director
+ 50000
24.2365 USD
3 years ago
Nov 30, 2021
Bought 242 K USD
Miller Steven D
Director
+ 10000
24.1699 USD
3 years ago
Aug 05, 2021
Bought 36.3 K USD
VON ESCHENBACH ANDREW C.
Director
+ 1400
25.94 USD
3 years ago
Aug 04, 2021
Bought 250 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
25.0123 USD
3 years ago
Jun 11, 2021
Sell 539 K USD
Eldessouky Sam
EVP & Chief Financial Officer
- 17000
31.6815 USD
3 years ago
Jun 02, 2021
Sell 3.86 M USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 121198
31.83 USD
3 years ago
May 26, 2021
Sell 351 K USD
WECHSLER AMY B
Director
- 11037
31.785 USD
4 years ago
Nov 23, 2020
Sell 29.1 K USD
Humphries William D.
President, Ortho-Dermatologics
- 1483
19.6328 USD
4 years ago
Nov 24, 2020
Sell 425 K USD
Humphries William D.
President, Ortho-Dermatologics
- 21658
19.6323 USD
4 years ago
Nov 27, 2020
Sell 268 K USD
Humphries William D.
President, Ortho-Dermatologics
- 13663
19.6302 USD
4 years ago
Sep 08, 2020
Sell 91.6 K USD
Humphries William D.
President, Ortho-Dermatologics
- 5667
16.17 USD
4 years ago
Jun 05, 2020
Bought 18.2 M USD
ValueAct Holdings, L.P.
Director
+ 948353
19.24 USD
4 years ago
Jun 05, 2020
Sell 18.2 M USD
ValueAct Holdings, L.P.
Director
- 948353
19.24 USD
4 years ago
May 14, 2020
Bought 9.31 M USD
Paulson John
+ 585100
15.92 USD
4 years ago
May 14, 2020
Bought 9.92 M USD
Paulson John
+ 624900
15.87 USD
4 years ago
May 14, 2020
Bought 1.1 M USD
Paulson John
+ 70000
15.65 USD
4 years ago
May 14, 2020
Bought 5.53 M USD
Paulson John
+ 348920
15.85 USD
4 years ago
May 13, 2020
Bought 10.8 M USD
Paulson John
+ 645844
16.7 USD
4 years ago
May 13, 2020
Bought 1.33 M USD
Paulson John
+ 80300
16.58 USD
4 years ago
May 13, 2020
Bought 9.86 M USD
Paulson John
+ 603900
16.32 USD
4 years ago
May 12, 2020
Bought 13.8 M USD
Paulson John
+ 799900
17.24 USD
4 years ago
May 12, 2020
Bought 11.9 M USD
Paulson John
+ 678400
17.47 USD
4 years ago
May 12, 2020
Bought 6.5 M USD
Paulson John
+ 374836
17.33 USD
4 years ago
May 12, 2020
Bought 2.85 M USD
Paulson John
+ 162900
17.5 USD
4 years ago
May 12, 2020
Bought 432 K USD
Paulson John
+ 25000
17.3 USD
4 years ago
Mar 12, 2020
Bought 38.8 K USD
Ross Thomas W. Sr.
Director
+ 2500
15.535 USD
4 years ago
Mar 10, 2020
Bought 80.1 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
+ 4390
18.2473 USD
4 years ago
Mar 10, 2020
Bought 20 K USD
VON ESCHENBACH ANDREW C.
Director
+ 1100
18.1785 USD
4 years ago
Mar 03, 2020
Bought 115 K USD
DE SCHUTTER RICHARD U
Director
+ 5000
23.083 USD
4 years ago
Mar 10, 2020
Bought 69.4 K USD
DE SCHUTTER RICHARD U
Director
+ 3800
18.2572 USD
5 years ago
Sep 13, 2019
Bought 699 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
23.31 USD
5 years ago
Aug 19, 2019
Sell 235 K USD
McKenna Mark C.
President, Salix
- 10773
21.8343 USD
5 years ago
Aug 16, 2019
Bought 650 K USD
Humphries William D.
President, Ortho-Dermatologics
+ 30703
21.1752 USD
5 years ago
Aug 12, 2019
Sell 76.7 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 3418
22.4475 USD
5 years ago
Jul 11, 2019
Sell 98.4 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 3968
24.81 USD
5 years ago
Feb 28, 2019
Bought 710 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
23.67 USD
6 years ago
Dec 14, 2018
Bought 584 K USD
APPIO THOMAS
Pres&Co-Head Bausch&Lomb/Int'l
+ 25440
22.9567 USD
6 years ago
Oct 15, 2018
Sell 382 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 15404
24.83 USD
6 years ago
Oct 16, 2018
Sell 116 K USD
ACKERMANN CHRISTINA
EVP AND GENERAL COUNSEL
- 4542
25.5 USD
6 years ago
Sep 13, 2018
Bought 3 M USD
DE SCHUTTER RICHARD U
Director
+ 125000
23.96 USD
6 years ago
Sep 14, 2018
Bought 226 K USD
Herendeen Paul
EVP and CFO
+ 10000
22.61 USD
6 years ago
Sep 14, 2018
Bought 670 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
22.32 USD
6 years ago
May 15, 2018
Bought 218 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
21.8 USD
6 years ago
May 15, 2018
Bought 327 K USD
DE SCHUTTER RICHARD U
Director
+ 15000
21.83 USD
6 years ago
Mar 13, 2018
Bought 241 K USD
Herendeen Paul
EVP and CFO
+ 15000
16.098 USD
6 years ago
Mar 13, 2018
Bought 482 K USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 30000
16.05 USD
6 years ago
Mar 08, 2018
Bought 153 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
15.34 USD
6 years ago
Mar 06, 2018
Bought 109 M USD
Paulson John
Director
+ 7066629
15.4 USD
6 years ago
Mar 06, 2018
Sell 109 M USD
Paulson John
Director
- 7066629
15.4 USD
7 years ago
Nov 17, 2017
Bought 143 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
14.33 USD
7 years ago
Nov 16, 2017
Bought 4.96 M USD
Paulson John
Director
+ 344216
14.3965 USD
7 years ago
Nov 16, 2017
Sell 4.95 M USD
Paulson John
Director
- 344216
14.3887 USD
7 years ago
Aug 21, 2017
Bought 70.3 K USD
DE SCHUTTER RICHARD U
Director
+ 4900
14.35 USD
7 years ago
Aug 21, 2017
Bought 73 K USD
DE SCHUTTER RICHARD U
Director
+ 5100
14.31 USD
7 years ago
May 11, 2017
Bought 278 K USD
DE SCHUTTER RICHARD U
Director
+ 20000
13.9 USD
7 years ago
Mar 15, 2017
Bought 108 K USD
DE SCHUTTER RICHARD U
Director
+ 10000
10.8 USD
7 years ago
Mar 14, 2017
Bought 257 K USD
Herendeen Paul
EVP and CFO
+ 24000
10.72 USD
8 years ago
Dec 14, 2016
Bought 73.6 K USD
Ross Thomas W. Sr.
Director
+ 5000
14.73 USD
8 years ago
Dec 12, 2016
Sell 51.6 M USD
Pershing Square Capital Management, L.P.
Director
- 3476690
14.85 USD
8 years ago
Dec 12, 2016
Bought 1.5 B USD
Pershing Square Capital Management, L.P.
Director
+ 9120000
165 USD
8 years ago
Aug 11, 2016
Bought 98.6 K USD
KARABELAS ARGERIS N
Director
+ 4000
24.65 USD
8 years ago
Jun 13, 2016
Bought 97.6 K USD
Ross Thomas W. Sr.
Director
+ 4000
24.4 USD
8 years ago
Jun 09, 2016
Sell 547 M USD
Pershing Square Capital Management, L.P.
Director
- 9120000
60 USD
8 years ago
Jun 09, 2016
Bought 5.47 M USD
Pershing Square Capital Management, L.P.
Director
+ 91200
60 USD
8 years ago
Jun 09, 2016
Sell 866 M USD
Pershing Square Capital Management, L.P.
Director
- 9120000
95 USD
8 years ago
Jun 09, 2016
Bought 547 M USD
Pershing Square Capital Management, L.P.
Director
+ 9120000
60 USD
8 years ago
Jun 10, 2016
Bought 4.94 M USD
PAPA JOSEPH C
CHAIRMAN & CEO
+ 202000
24.48 USD
9 years ago
Nov 05, 2015
Sell 11 M USD
Pearson J. Michael
Chief Executive Officer
- 147054
74.67 USD
9 years ago
Nov 05, 2015
Sell 61.4 M USD
Pearson J. Michael
Chief Executive Officer
- 800345
76.66 USD
9 years ago
Nov 05, 2015
Sell 29.5 M USD
Pearson J. Michael
Chief Executive Officer
- 350000
84.26 USD
9 years ago
Oct 21, 2015
Bought 79.4 K USD
Farmer Ronald Harold
Director
+ 500
158.79 USD
9 years ago
Oct 21, 2015
Bought 193 K USD
Farmer Ronald Harold
Director
+ 1000
193 USD
9 years ago
Aug 26, 2015
Bought 110 K USD
Farmer Ronald Harold
Director
+ 500
220 USD
9 years ago
Aug 21, 2015
Bought 157 K USD
Farmer Ronald Harold
Director
+ 700
224.97 USD
9 years ago
Aug 21, 2015
Bought 67.5 K USD
Farmer Ronald Harold
Director
+ 300
224.98 USD
9 years ago
Jul 31, 2015
Bought 181 K USD
Rosiello Robert L.
EVP, Chief Financial Officer
+ 704
257.25 USD
9 years ago
Jul 30, 2015
Bought 1.82 M USD
Rosiello Robert L.
EVP, Chief Financial Officer
+ 7171
253.99 USD
9 years ago
Jun 12, 2015
Bought 3 M USD
Rosiello Robert L.
Executive Vice President
+ 12900
232.51 USD
9 years ago
Jun 10, 2015
Sell 96.4 M USD
UBBEN JEFFREY W
Director
- 417919
230.6 USD
9 years ago
Jun 10, 2015
Sell 764 M USD
UBBEN JEFFREY W
Director
- 3488933
219 USD
9 years ago
Jun 10, 2015
Sell 7.23 M USD
UBBEN JEFFREY W
Director
- 31358
230.6 USD
9 years ago
Jun 10, 2015
Sell 57.3 M USD
UBBEN JEFFREY W
Director
- 261790
219 USD
9 years ago
Jun 08, 2015
Bought 145 K USD
Farmer Ronald Harold
Director
+ 500
289.2 USD
9 years ago
Jun 09, 2015
Bought 116 K USD
Farmer Ronald Harold
Director
+ 500
232.05 USD
9 years ago
Jun 01, 2015
Sell 24 K USD
Mirovsky Pavel
EVP, Pres. & GM Valeant EMENA
- 100
240 USD
9 years ago
Jun 02, 2015
Sell 3.55 M USD
Mirovsky Pavel
EVP, Pres. & GM Valeant EMENA
- 14900
237.94 USD
9 years ago
Jun 02, 2015
Sell 5.48 M USD
Mirovsky Pavel
EVP, Pres. & GM Valeant EMENA
- 23000
238.044 USD
9 years ago
May 26, 2015
Bought 585 K USD
Whitaker Anne Clem
Director
+ 2500
234 USD
9 years ago
May 26, 2015
Bought 1.18 M USD
Whitaker Anne Clem
Director
+ 5000
235 USD
9 years ago
May 04, 2015
Sell 20.2 M USD
Chai-Onn Robert Roswell
EVP, CLO, General Counsel
- 90938
222.5411 USD
9 years ago
Mar 02, 2015
Sell 18.2 M USD
Chai-Onn Robert Roswell
EVP, CLO, General Counsel
- 90939
200.0142 USD
10 years ago
Dec 12, 2014
Bought 80.2 K USD
Farmer Ronald Harold
Director
+ 500
160.48 USD
10 years ago
Dec 10, 2014
Bought 6.96 M USD
UBBEN JEFFREY W
Director
+ 50000
139.29 USD
10 years ago
Dec 09, 2014
Bought 28 M USD
UBBEN JEFFREY W
Director
+ 200000
140.25 USD
10 years ago
Dec 03, 2014
Bought 219 K USD
STEVENSON KATHARINE BERGHUIS
Director
+ 1500
145.73 USD
10 years ago
Nov 24, 2014
Bought 164 K USD
Farmer Ronald Harold
Director
+ 1000
163.95 USD
10 years ago
Nov 24, 2014
Bought 29.9 M USD
UBBEN JEFFREY W
Director
+ 210000
142.25 USD
7. News
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit organization dedicated to curing glaucoma, are launching the second annual “Faces of Glaucoma” campaign. The campaign, which will highlight diverse patient stories and raise awareness of the second leading cause of blindness worldwide,1 will take place throughout Glau. businesswire.com - 1 week ago
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, M.D., will participate in a company presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. businesswire.com - 2 weeks ago
Contact lens maker Bausch + Lomb says it is exploring sale Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company. reuters.com - 1 month ago
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO): "As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. accesswire.com - 1 month ago
Bausch + Lomb Responds to Rumors of a Potential Sale VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO): “The Bausch + Lomb Board of Directors authorized management and its advisors to explore a potential sale, which is one of several options being explored to complete a full separation from Bausch Health Companies. businesswire.com - 1 month ago
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday. benzinga.com - 1 month ago
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News Bausch Health Companies Inc.'s debt burden remains a critical issue, with over $21 billion in long-term debt, making a sale of Bausch + Lomb Corporation a potential solution. Bausch + Lomb's Q3 performance showed revenue growth and a shift to net income, driven by new products like Xiidra and Miebo. Despite bankruptcy rumors, major institutional investors like Carl Icahn and Paulson & Co. suggest strategic moves could prevent such an outcome. seekingalpha.com - 1 month ago
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. accesswire.com - 1 month ago
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors Bausch Health Companies is undervalued, with a positive outlook for 2024 and solvency reassurance for 2025. The complete spin-off of Bausch + Lomb (B+L) will benefit BHC and is expected to improve its future profitability and financial health. BHC's innovative pipeline and proven track record of innovation will offset revenue loss from the spin-off and support future growth. seekingalpha.com - 1 month ago
Why Is Bausch (BHC) Down 11.7% Since Last Earnings Report? Bausch (BHC) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Bausch (BHC) Upgraded to Buy: Here's What You Should Know Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan. reuters.com - 2 months ago
8. Profile Summary

Bausch Health Companies Inc. BHC

image
COUNTRY CA
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 2.74 B
Dividend Yield 0.00%
Description Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Contact 2150 St. ElzEar Boulevard West, Laval, QC, H7L 4A8 https://www.bauschhealth.com
IPO Date March 29, 1994
Employees 20270
Officers Ms. Seana Carson Executive Vice President & General Counsel Mr. Cees Heiman Senior Vice President of Europe & Canada Ms. Jiny Kim M.B.A. Senior Vice President of Solta Medical Mr. Jean-Jacques Charhon Executive Vice President & Chief Financial Officer Mr. Mirza Dautbegovic Executive Vice President & Chief Operating Officer Ms. Aimee J. Lenar Executive Vice President of US Pharma Mr. Garen Sarafian Vice President & Head of Investor Relations Ms. Kathleen Fitzpatrick Executive Vice President and Chief HR & Communications Officer Mr. Donald Pearl Senior Vice President of Ortho Dermatologics Mr. Thomas J. Appio Chief Executive Officer & Director